Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PHVS Pharvaris N.V.

交易中 07-06 15:29:47 EDT

33.52

-0.34

-1.02%

最高34.98	最低33.06	成交量56.96万
今开34.12	昨收33.86	日振幅5.66%
总市值23.41亿	流通市值14.19亿	总股本6,986万
成交额1,918万	换手率1.35%	流通股本4,235万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PHVS","market":"US","secType":"STK","nameCN":"Pharvaris N.V.","latestPrice":33.515,"timestamp":1783366187075,"preClose":33.86,"halted":0,"volume":569643,"delay":0,"changeRate":-0.010189013585351413,"floatShares":42352000,"shares":69863685,"eps":-3.141599,"marketStatus":"交易中","change":-0.345,"latestTime":"07-06 15:29:47 EDT","open":34.12,"high":34.975,"low":33.06,"amount":19182166.926645,"amplitude":0.056556,"askPrice":33.55,"askSize":13,"bidPrice":33.48,"bidSize":226,"shortable":3,"etf":0,"ttmEps":-3.141599,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783368000000},"marketStatusCode":2,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":33.86,"preHourTrading":{"tag":"盘前","latestPrice":34.14,"preClose":33.86,"latestTime":"09:29 EDT","volume":391,"amount":13431.278927000001,"timestamp":1783344599999,"change":0.28,"changeRate":0.008269,"amplitude":0.071471},"postHourTrading":{"tag":"盘后","latestPrice":33.86,"preClose":33.86,"latestTime":"16:10 EDT","volume":927,"amount":31388.22,"timestamp":1783023005207,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.985823,"impliedVol":0.7844,"impliedVolPercentile":0.6358},"requestUrl":"/m/hq/s/PHVS/tweets","defaultTab":"tweets","newsList":[{"id":"1117544416","title":"Pharvaris N.V.宣布FDA受理Deucrictibant Ir用于遗传性血管水肿急性发作按需治疗的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1117544416","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117544416?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:51","pubTimestamp":1783335095,"startTime":"0","endTime":"0","summary":"Pharvaris N.V. 宣布，美国食品药品监督管理局（FDA）已正式受理其新药Deucrictibant Ir用于遗传性血管水肿急性发作按需治疗的新药申请。这一进展标志着该药物在监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118810953","title":"Pharvaris N.V. 完成承销发行定价：以每股29.68美元发售3,874,664股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118810953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118810953?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:03","pubTimestamp":1778234627,"startTime":"0","endTime":"0","summary":"生物制药公司Pharvaris N.V. 已确定其普通股的承销公开发行定价。本次发行规模为3,874,664股普通股，每股定价为29.68美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616324089","title":"Pharvaris N.V.盘中异动 急速下跌5.37%报26.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616324089?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:53","pubTimestamp":1772549591,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时53分，Pharvaris N.V.股票出现波动，股价大幅下跌5.37%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为1.40%。Pharvaris 利用新型小分子药物直接靶向这一临床治疗靶点，并凭借在 2 期预防和 HAE 研究中取得的积极数据，正在开发 deucrictibant。Pharvaris 目前正在招募一项治疗 HAE 的关键性 3 期试验，并计划启动一项用于预防 HAE 的关键性 3 期 deucrictibant 试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303225311a69e1156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303225311a69e1156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518979278","title":"Pharvaris N.V.盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518979278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518979278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613493,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Pharvaris N.V.股票出现波动，股价快速拉升5.26%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.59%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213133964035b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517600731","title":"Pharvaris N.V.盘中异动 急速跳水5.67%报14.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517600731?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:44","pubTimestamp":1741279483,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时44分，Pharvaris N.V.股票出现波动，股价快速下挫5.67%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.33%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307004444abeb97e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307004444abeb97e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517928498","title":"Pharvaris N.V.盘中异动 下午盘大幅下挫6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517928498","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517928498?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:38","pubTimestamp":1741199916,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时38分，Pharvaris N.V.股票出现波动，股价大幅跳水6.15%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.43%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306023836963b123e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306023836963b123e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516363742","title":"Citizens Capital Markets：重申Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由55.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516363742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516363742?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由55.00美元调整至55.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509478557","title":"Pharvaris N.V.盘中异动 股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509478557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509478557?lang=zh_cn&edition=full","pubTime":"2025-02-07 03:54","pubTimestamp":1738871677,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日03时54分，Pharvaris N.V.股票出现波动，股价快速上涨5.19%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.53%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207035439961a47a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207035439961a47a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508988919","title":"摩根大通证券公司：维持Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由46.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508988919","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508988919?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:13","pubTimestamp":1738343582,"startTime":"0","endTime":"0","summary":"摩根大通证券公司：维持Pharvaris(PHVS.US)评级，由优于大市调整至优于大市评级, 目标价由46.00美元调整至55.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01011347922518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PHVS","159848","399975"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506894971","title":"Pharvaris N.V.盘中异动 大幅跳水5.12%报18.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506894971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506894971?lang=zh_cn&edition=full","pubTime":"2025-01-25 02:55","pubTimestamp":1737744922,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日02时55分，Pharvaris N.V.股票出现波动，股价大幅下挫5.12%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.15%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025522960fb70d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025522960fb70d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505527254","title":"Pharvaris N.V.盘中异动 早盘股价大涨6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505527254","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505527254?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:50","pubTimestamp":1737471048,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时50分，Pharvaris N.V.股票出现异动，股价快速上涨6.21%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.15%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225048a22a5bab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225048a22a5bab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504195539","title":"Pharvaris N.V.盘中异动 快速上涨5.10%报18.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504195539?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:48","pubTimestamp":1737128887,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时48分，Pharvaris N.V.股票出现异动，股价快速拉升5.10%。截至发稿，该股报18.34美元/股，成交量6325股，换手率0.01%，振幅4.41%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.83%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172348079607aa5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172348079607aa5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503585586","title":"Pharvaris N.V.盘中异动 早盘股价大跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503585586","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503585586?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:33","pubTimestamp":1736778796,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时33分，Pharvaris N.V.股票出现异动，股价大幅跳水5.73%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.98%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132233169864d617&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132233169864d617&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502811772","title":"Pharvaris N.V.盘中异动 下午盘急速下跌5.50%报17.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502811772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502811772?lang=zh_cn&edition=full","pubTime":"2025-01-11 04:02","pubTimestamp":1736539349,"startTime":"0","endTime":"0","summary":"北京时间2025年01月11日04时02分，Pharvaris N.V.股票出现异动，股价快速下挫5.50%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为2.21%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011104022995ffaa13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011104022995ffaa13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501735593","title":"Pharvaris N.V.盘中异动 下午盘急速上涨7.31%报19.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501735593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501735593?lang=zh_cn&edition=full","pubTime":"2025-01-08 02:21","pubTimestamp":1736274094,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日02时21分，Pharvaris N.V.股票出现异动，股价急速拉升7.31%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为1.31%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108022134aba2101d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108022134aba2101d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500690642","title":"Pharvaris N.V.盘中异动 股价大跌5.06%报18.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500690642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500690642?lang=zh_cn&edition=full","pubTime":"2025-01-03 03:17","pubTimestamp":1735845426,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日03时17分，Pharvaris N.V.股票出现波动，股价急速下挫5.06%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.26%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010303170698593647&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010303170698593647&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495752873","title":"Pharvaris N.V.盘中异动 股价大跌6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495752873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495752873?lang=zh_cn&edition=full","pubTime":"2024-12-30 22:35","pubTimestamp":1735569304,"startTime":"0","endTime":"0","summary":"北京时间2024年12月30日22时35分，Pharvaris N.V.股票出现异动，股价快速下跌6.43%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.60%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123022350495f2c386&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123022350495f2c386&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2494386034","title":"Pharvaris N.V.盘中异动 股价大涨6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494386034","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494386034?lang=zh_cn&edition=full","pubTime":"2024-12-27 00:24","pubTimestamp":1735230257,"startTime":"0","endTime":"0","summary":"北京时间2024年12月27日00时24分，Pharvaris N.V.股票出现异动，股价快速上涨6.21%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.26%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227002417a20aad70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227002417a20aad70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493885429","title":"Pharvaris N.V.盘中异动 临近午盘股价大涨5.63%报20.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493885429","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493885429?lang=zh_cn&edition=full","pubTime":"2024-12-21 00:52","pubTimestamp":1734713555,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日00时52分，Pharvaris N.V.股票出现波动，股价快速上涨5.63%。Pharvaris N.V.股票所在的生物技术行业中，整体涨幅为0.37%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221005235984cfe9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221005235984cfe9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491372977","title":"Pharvaris N.V.盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491372977","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491372977?lang=zh_cn&edition=full","pubTime":"2024-12-14 00:11","pubTimestamp":1734106268,"startTime":"0","endTime":"0","summary":"北京时间2024年12月14日00时11分，Pharvaris N.V.股票出现异动，股价急速跳水5.10%。Pharvaris N.V.股票所在的生物技术行业中，整体跌幅为0.44%。Pharvaris N.V.公司简介：Pharvaris NV是一家后期阶段的生物制药公司，开发新型口服缓激肽B2受体拮抗剂，以预防和治疗遗传性血管性水肿症发作。Pharvaris目前正在进行一项治疗遗传性血管性水肿症发作的关键 3 期研究，并计划启动一项deucrictibant预防遗传性血管性水肿症发作的关键 3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241214001108984bdb63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241214001108984bdb63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHVS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharvaris.com","stockEarnings":[{"period":"1week","weight":0.0168},{"period":"1month","weight":0.1684},{"period":"3month","weight":0.1856},{"period":"6month","weight":0.2787},{"period":"1year","weight":0.9001},{"period":"ytd","weight":0.2202}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pharvaris N.V.于2015年9月30日注册在荷兰成立。该公司是一家临床阶段的生物制药公司，专注于开发deucrictibant，一种口服小分子缓激肽B2受体拮抗剂，用于治疗遗传性血管性水肿。其研发管线包括用于按需治疗的速释胶囊和用于预防的缓释片，两者均已完成2期和3期试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.009318},{"month":2,"riseRate":0.2,"avgChangeRate":-0.077124},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.036334},{"month":4,"riseRate":0.666667,"avgChangeRate":0.050541},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.089125},{"month":6,"riseRate":0.666667,"avgChangeRate":0.182631},{"month":7,"riseRate":0.333333,"avgChangeRate":0.014263},{"month":8,"riseRate":0.8,"avgChangeRate":-0.020522},{"month":9,"riseRate":0.6,"avgChangeRate":-0.015739},{"month":10,"riseRate":0.2,"avgChangeRate":-0.072433},{"month":11,"riseRate":0.4,"avgChangeRate":-0.106545},{"month":12,"riseRate":0.4,"avgChangeRate":0.958602}],"exchange":"NASDAQ","name":"Pharvaris N.V.","nameEN":"Pharvaris N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pharvaris N.V.,PHVS,Pharvaris N.V.股票,Pharvaris N.V.股票老虎,Pharvaris N.V.股票老虎国际,Pharvaris N.V.行情,Pharvaris N.V.股票行情,Pharvaris N.V.股价,Pharvaris N.V.股市,Pharvaris N.V.股票价格,Pharvaris N.V.股票交易,Pharvaris N.V.股票购买,Pharvaris N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharvaris N.V.(PHVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pharvaris N.V.(PHVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}